Daiichi planning regulatory submissions for AML candidate

Daiichi Sankyo Co. Ltd. (Tokyo:4568) said quizartinib met the primary endpoint of improving overall survival (OS) vs. salvage chemotherapy in the Phase III QuANTUM-R trial to treat relapsed or refractory acute myelogenous

Read the full 322 word article

User Sign In